Societe Generale issued a report on Bayer (ETR:BAYN), hiking its stock price target to 105.00EUR earlier today
- Updated: September 15, 2016
Reporting a possible upside of 0.15%, Societe Generale bumped the price target of Bayer (ETR:BAYN) to 105EUR.
On 8/29/2016, Citigroup Corp. reported about Bayer(ETR:BAYN) raised the target price from 0.00EUR to 120.00EUR that suggested an upside of 0.24%.
Having a price of 91.44EUR, Bayer (ETR:BAYN) traded 7.14% lower on the day. The last close is up 1.82% relative to the 200-day moving average, compared with the S&P 500 which has fallen -0.01% over the same time period. The company has logged a 50-day average of 0.04EUR and 200-day moving average of 0.03EUR. Volume of trade was was up over the average, with 10,000 shares of BAYN changing hands over the typical 211 shares.
Recent Performance Graph:
Bayer has a one-year low of 0.03EUR and a 52 week high of 0.04EUR and has a market capitalization of 0.0 EUR.
About Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, and adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.